Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. Scilipoti P, Longoni M, de Angelis M, Zaurito P, et al. BJU Int 2025 Jan 11. doi: 10.1111/bju.16645.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Scilipoti P, Longoni M, de Angelis M, Zaurito P, et al. Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results. BJU Int 2025 Jan 11. doi: 10.1111/bju.16645.
PMID: 39797535